202 related articles for article (PubMed ID: 32905903)
1. Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity.
Schetters STT; Li RJE; Kruijssen LJW; Engels S; Ambrosini M; Garcia-Vallejo JJ; Kalay H; Unger WWJ; van Kooyk Y
Biomaterials; 2020 Dec; 262():120342. PubMed ID: 32905903
[TBL] [Abstract][Full Text] [Related]
2. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
3. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
[TBL] [Abstract][Full Text] [Related]
4. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.
Salem ML; Kadima AN; Cole DJ; Gillanders WE
J Immunother; 2005; 28(3):220-8. PubMed ID: 15838378
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
6. Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination.
Hulett TW; Jensen SM; Wilmarth PA; Reddy AP; Ballesteros-Merino C; Afentoulis ME; Dubay C; David LL; Fox BA
J Immunother Cancer; 2018 Apr; 6(1):27. PubMed ID: 29618380
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
8. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
9. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
10. A novel peptide vaccination augments cytotoxic CD8
Lew MH; Norazmi MN; Nordin F; Tye GJ
Immunobiology; 2022 May; 227(3):152201. PubMed ID: 35272134
[TBL] [Abstract][Full Text] [Related]
11. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
12. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
[TBL] [Abstract][Full Text] [Related]
13. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy.
Tuettenberg A; Jonuleit H; Tüting T; Brück J; Knop J; Enk AH
Gene Ther; 2003 Feb; 10(3):243-50. PubMed ID: 12571632
[TBL] [Abstract][Full Text] [Related]
14. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
[TBL] [Abstract][Full Text] [Related]
15. High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
Carretero-Iglesia L; Couturaud B; Baumgaertner P; Schmidt J; Maby-El Hajjami H; Speiser DE; Hebeisen M; Rufer N
Front Immunol; 2019; 10():3016. PubMed ID: 31969886
[TBL] [Abstract][Full Text] [Related]
16. Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.
Schetters STT; Kruijssen LJW; Crommentuijn MHW; Kalay H; Ochando J; den Haan JMM; Garcia-Vallejo JJ; van Kooyk Y
Front Immunol; 2018; 9():990. PubMed ID: 29867967
[TBL] [Abstract][Full Text] [Related]
17. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Rammensee HG; Wiesmüller KH; Chandran PA; Zelba H; Rusch E; Gouttefangeas C; Kowalewski DJ; Di Marco M; Haen SP; Walz JS; Gloria YC; Bödder J; Schertel JM; Tunger A; Müller L; Kießler M; Wehner R; Schmitz M; Jakobi M; Schneiderhan-Marra N; Klein R; Laske K; Artzner K; Backert L; Schuster H; Schwenck J; Weber ANR; Pichler BJ; Kneilling M; la Fougère C; Forchhammer S; Metzler G; Bauer J; Weide B; Schippert W; Stevanović S; Löffler MW
J Immunother Cancer; 2019 Nov; 7(1):307. PubMed ID: 31730025
[TBL] [Abstract][Full Text] [Related]
18. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
19. Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines.
Qiu F; Becker KW; Knight FC; Baljon JJ; Sevimli S; Shae D; Gilchuk P; Joyce S; Wilson JT
Biomaterials; 2018 Nov; 182():82-91. PubMed ID: 30107272
[TBL] [Abstract][Full Text] [Related]
20. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
